Please assess the completion status of the following clinical trial:

Trial Title: Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be healthy based on medical history, laboratory work, and physical exam~* Be ≥18 and ≤65 years of age~* Females of childbearing potential must not be pregnant and be using an acceptable form of birth control~* Must be free of any systemic or dermatologic disorder~Key Exclusion Criteria:~* Use of prescription medication within 14 days or over-the-counter products within 7 days prior to study medication~* Current use of opioids~* Known hypersensitivity or allergy to any of the components of the product formulations~* Any serious illness in the 4 weeks preceding the beginning of treatment that resulted in missed work or hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Sequence AB) (Type: EXPERIMENTAL): Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
- Lidocaine Patch (Sequence BA) (Type: EXPERIMENTAL): Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).